Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial

医学 透析 随机对照试验 整群随机对照试验 心肌梗塞 星团(航天器) 冲程(发动机) 心力衰竭 急诊医学 物理疗法 内科学 计算机科学 机械工程 工程类 程序设计语言
作者
Amit X. Garg,Ahmed A. Al‐Jaishi,Stephanie N. Dixon,Jessica M. Sontrop,Sierra Anderson,Amit Bagga,Derek Benjamin,William AD Berry,Peter G. Blake,Laura C Chambers,Patricia C.K. Chan,Nicole Delbrouck,Philip James Devereaux,Richard Goluch,Laura Gregor,Jeremy Grimshaw,Garth J Hanson,Eduard A Illiescu,Arsh Kumar Jain,Lauren Killin
出处
期刊:The Lancet [Elsevier BV]
卷期号:400 (10364): 1693-1703 被引量:76
标识
DOI:10.1016/s0140-6736(22)01805-0
摘要

Haemodialysis centres have conventionally provided maintenance haemodialysis using a standard dialysate temperature (eg, 36·5°C) for all patients. Many centres now use cooler dialysate (eg, 36·0°C or lower) for potential cardiovascular benefits. We aimed to assess whether personalised cooler dialysate, implemented as centre-wide policy, reduced the risk of cardiovascular-related death or hospital admission compared with standard temperature dialysate.MyTEMP was a pragmatic, two-arm, parallel-group, registry-based, open-label, cluster-randomised, superiority trial done at haemodialysis centres in Ontario, Canada. Eligible centres provided maintenance haemodialysis to at least 15 patients a week, and the medical director of each centre had to confirm that their centre would deliver the assigned intervention. Using covariate-constrained randomisation, we allocated 84 centres (1:1) to use either personalised cooler dialysate (nurses set the dialysate temperature 0·5-0·9°C below each patient's measured pre-dialysis body temperature, with a lowest recommended dialysate temperature of 35·5°C), or standard temperature dialysate (36·5°C for all patients and treatments). Patients and health-care providers were not masked to the group assignment; however, the primary outcome was recorded in provincial databases by medical coders who were unaware of the trial or the centres' group assignment. The primary composite outcome was cardiovascular-related death or hospital admission with myocardial infarction, ischaemic stroke, or congestive heart failure during the 4-year trial period. Analysis was by intention to treat. The study is registered at ClinicalTrials.gov, NCT02628366.We assessed all of Ontario's 97 centres for inclusion into the study. Nine centres had less than 15 patients and one director requested that four of their seven centres not participate. 84 centres were recruited and on Feb 1, 2017, these centres were randomly assigned to administer personalised cooler dialysate (42 centres) or standard temperature dialysate (42 centres). The intervention period was from April 3, 2017, to March 31, 2021, and during this time the trial centres provided outpatient maintenance haemodialysis to 15 413 patients (about 4·3 million haemodialysis treatments). The mean dialysate temperature was 35·8°C in the cooler dialysate group and 36·4°C in the standard temperature group. The primary outcome occurred in 1711 (21·4%) of 8000 patients in the cooler dialysate group versus 1658 (22·4%) of 7413 patients in the standard temperature group (adjusted hazard ratio 1·00, 96% CI 0·89 to 1·11; p=0·93). The mean drop in intradialytic systolic blood pressure was 26·6 mm Hg in the cooler dialysate group and 27·1 mm Hg in the standard temperature group (mean difference -0·5 mm Hg, 99% CI -1·4 to 0·4; p=0·14).Centre-wide delivery of personalised cooler dialysate did not significantly reduce the risk of major cardiovascular events compared with standard temperature dialysate. The rising popularity of cooler dialysate is called into question by this study, and the risks and benefits of cooler dialysate in some patient populations should be clarified in future trials.Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Ontario Renal Network, Ontario Strategy for Patient-Oriented Research Support Unit, Dialysis Clinic, Inc., ICES (formerly known as the Institute for Clinical Evaluative Sciences), Lawson Health Research Institute, and Western University.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
梦在远方完成签到 ,获得积分10
刚刚
刚刚
fjy完成签到,获得积分10
2秒前
diguohu完成签到,获得积分10
2秒前
科研通AI6.4的应助被01采纳,获得10
2秒前
乐乐的应助被01采纳,获得10
3秒前
清欢发布了新的文献求助10
3秒前
hyy发布了新的文献求助10
3秒前
嘻嘻哈哈的应助被开心德地采纳,获得10
3秒前
3秒前
天天快乐的应助被朱晖采纳,获得10
4秒前
爆米花的应助被楠楠采纳,获得10
4秒前
露露完成签到,获得积分10
4秒前
多喝水完成签到 ,获得积分10
4秒前
5秒前
在水一方的应助被Kyra采纳,获得10
5秒前
jqkx完成签到,获得积分10
5秒前
静默发布了新的文献求助10
7秒前
V_发布了新的文献求助10
7秒前
科研通AI6.3的应助被Applennessy采纳,获得10
7秒前
华仔的应助被uri采纳,获得10
7秒前
万能图书馆的应助被光亮珊采纳,获得10
7秒前
秋风的应助被DW采纳,获得30
8秒前
青年才俊完成签到,获得积分10
9秒前
9秒前
to_the_end完成签到,获得积分10
10秒前
今后的应助被儒雅绿草采纳,获得10
10秒前
10秒前
10秒前
11秒前
Jasper的应助被科研通管家采纳,获得10
11秒前
嘻嘻哈哈的应助被开心德地采纳,获得10
11秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
11秒前
共享精神的应助被科研通管家采纳,获得10
11秒前
风趣的雪柳完成签到,获得积分10
11秒前
无花果的应助被科研通管家采纳,获得10
12秒前
12秒前
12秒前
小二郎的应助被科研通管家采纳,获得10
12秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188210
求助须知:如何正确求助?哪些是违规求助? 9576001
关于积分的说明 21844898
捐赠科研通 7786081
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482139